Indoco Remedies Ltd

Indoco Remedies Ltd share price gained 0.39% to Rs 220.65 after the company's net profit tumbled by 70.25% to Rs 19.47 crore, while revenue from operations slightly gained 8.73% to Rs 506.92 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, gaining 4.06%. It has marginally improved by 3.17% over last one week and softened by 0.26% in last one month while the market capitalization of Indoco Remedies Ltd has softened by 5.44% and 1.68% in the same period respectively. Profit before tax (PBT) of Indoco Remedies Ltd stood at Rs 24.19 crore in Q3 FY26, crashing by 278.79% year-on-year, and plunging by 68.88% quarter-on-quarter. EBITDA came in at Rs 44 crore, rising 5.13% YoY and heading higher 14.47% sequentially. Total expenses rose by 10.23% to Rs 508.18 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 127.63 crore, jumping 22.04% YoY, while employee benefits expense was at Rs 105.11 crore, inching up 3.65% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 9.24% to Rs 1792.94 crore, while net profit soared by 26.62% to Rs 98.7 crore, compared to previous TTM. EBITDA jumped by 10542% to Rs 138.47 crore, and PBT surged 43.22% to Rs 106.51 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 192.23 crore in FY26, as against Rs 93.94 crore in FY25. Indoco Remedies Ltd crashed 20.31% in last one year, underperforming the benchmark BSE Sensex which has slipped by 13.19% during the same period.

Indoco Remedies Ltd share price declined by 3.30% to Rs 219.8 after the company's net profit tumbled by 70.25% to Rs 19.47 crore, while revenue from operations improved marginally 8.73% to Rs 506.92 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, gaining 3.34%. It has improved by 0.07% over last one week and edged lower by 3.01% in last one month while the market capitalization of Indoco Remedies Ltd has eased by 6.90% and 2.38% in the same period respectively. Profit before tax (PBT) of Indoco Remedies Ltd stood at Rs 24.19 crore in Q3 FY26, crashing by 278.79% year-on-year, and nosediving by 68.88% quarter-on-quarter. EBITDA came in at Rs 44 crore, rising 5.13% YoY and improving 14.47% sequentially. Total expenses increased by 10.23% to Rs 508.18 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 127.63 crore, soaring by 22.04% YoY, while employee benefits expense was at Rs 105.11 crore, easing 3.65% YoY. For the TTM ended FY26, revenue from operations grew marginally by 9.24% to Rs 1792.94 crore, while net profit surged by 26.62% to Rs 98.7 crore, compared to previous TTM. EBITDA jumped by 10542% to Rs 138.47 crore, and PBT soared 43.22% to Rs 106.51 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 192.23 crore in FY26, as against Rs 93.94 crore in FY25. Indoco Remedies Ltd plunged by 20.62% in last one year, underperforming the benchmark BSE Sensex which has reduced by 13.18% during the same period.

Indoco Remedies Limited announced that its Nomination and Remuneration Committee approved the allotment of 14,850 equity shares of Rs 2 face value each to the Indoco Employees Welfare Trust under the Indoco Remedies Limited Employee Stock Option Plan – 2022, increasing the company's paid-up capital from Rs 18,46,07,210 (9,23,03,605 equity shares) to Rs 18,46,36,910 (9,23,18,455 equity shares).

Indoco Remedies Limited will hold a board meeting on Tuesday, October 27, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing. The trading window for dealing in equity shares of Indoco Remedies Limited will remain closed for designated persons and their immediate relatives until October 29, 2026.

Indoco Remedies Limited informed the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited that MUFG Intime India Private Limited, formerly Link Intime India Private Limited, has confirmed compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

Indoco Remedies Limited announced the incorporation of a wholly owned subsidiary, Warren Lifesciences Private Limited, on September 26, 2026, under the Companies Act, 2013. Warren Lifesciences Private Limited has an authorized share capital of Rs 100,000 divided into 10,000 equity shares of Rs 10 each, and will focus on the manufacture, development, and sale of pharmaceutical products, including active pharmaceutical ingredients and finished formulations. Indoco Remedies will hold 100% of the subsidiary's paid-up share capital through a cash consideration of Rs 10 per share.

Indoco Remedies Limited will close its trading window for equity shares from October 1, 2026, until 48 hours after the declaration of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, in accordance with SEBI regulations and company policy.

Indoco Remedies Limited announced that its Committee of Executive Directors has approved the incorporation of a wholly owned subsidiary, Warren Lifesciences Private Limited, for which name approval has been received from the Registrar of Companies, Mumbai. The new company, to be incorporated in India, will operate in the pharmaceutical sector and intends to manufacture, develop, and sell pharmaceutical products including active pharmaceutical ingredients, finished formulations, and key starting materials, with Indoco Remedies Limited holding 100% shareholding and an authorized and paid-up equity share capital of Rs 1,00,000 divided into 10,000 equity shares of Rs 10 each.

Indoco Remedies Limited announced it executed a deed of conveyance on August 27, 2026, to sell a plot of land measuring approximately 2,876.08 square meters to Kalpataru Townships Private Limited for Rs 64,00,00,000. The company stated the sale will not impact its business operations and does not constitute a substantial undertaking, and that no related parties are involved.

Indoco Remedies Limited has fixed Thursday, September 10, 2026, as the record date for determining entitlement to a final dividend of Rs 0.20 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the Annual General Meeting scheduled for September 17, 2026; the company’s register of members and share transfer books will remain closed from September 11, 2026, to September 17, 2026, and Thursday, September 10, 2026, is also the cut-off date for remote e-voting and e-voting during the AGM.